Mirum Pharmaceuticals (MEX:MIRM) Inventories, Finished Goods: MXN62 Mil (As of Mar. 2026)


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN849.96
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Inventories, Finished Goods?

Mirum Pharmaceuticals MEX:MIRM 46 Inventories, Finished Goods is MXN62 Mil as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN849.96. The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's quarterly finished goods increased from Sep. 2025 (MXN52 Mil) to Dec. 2025 (MXN63 Mil) but then declined from Dec. 2025 (MXN63 Mil) to Mar. 2026 (MXN62 Mil).

Mirum Pharmaceuticals's annual finished goods declined from Dec. 2023 (MXN160 Mil) to Dec. 2024 (MXN68 Mil) and declined from Dec. 2024 (MXN68 Mil) to Dec. 2025 (MXN63 Mil).

Mirum Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Inventories, Finished Goods Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial 1.79 4.17 160.25 68.49 63.31

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.14 69.82 52.23 63.31 61.64
MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN62 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Inventories, Finished Goods of MXN62 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Inventories, Finished Goods too high?
Mirum Pharmaceuticals' current Inventories, Finished Goods is MXN62 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Inventories, Finished Goods compare to RYTM and SYRE?
Mirum Pharmaceuticals' Inventories, Finished Goods of MXN62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Inventories, Finished Goods is MXN62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Inventories, Finished Goods of MXN62 Mil. The stock's GF Value™ is MXN849.96, compared to a current price of MXN1,256.12 — trading 47.8% above its estimated fair value. The current Inventories, Finished Goods is MXN62 Mil. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Inventories, Finished Goods is MXN62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 47.8% above its estimated GF Value™ of MXN849.96.

Key valuation signals for MEX:MIRM:

  • Inventories, Finished Goods: MXN62 Mil
  • GF Value™: MXN849.96 vs. price of MXN1,256.12 (47.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN849.96
GF Value